Printer Friendly

MARION MERRELL DOW EXERCISES RIGHT TO LICENSE GENSIA ARA COMPOUND

MARION MERRELL DOW EXERCISES RIGHT TO LICENSE GENSIA ARA COMPOUND
 SAN DIEGO, July 27 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that Marion Merrell Dow Inc. (NYSE: MKC) has exercised its right under a Technology Option and Licensing Agreement signed in January 1990, to license and continue development of GP-1-468-3, an adenosine regulating agent (ARA) which is expected to be investigated for the treatment of chronic cardiovascular disease. By exercising its right under the agreement, Marion Merrell Dow has agreed to pay a license fee to Gensia, payable upon completion of the final licensing agreement. Marion Merrell Dow also will make additional payments should certain development and regulatory milestones be achieved with GP-1-468-3. Gensia also will receive a royalty on net sales of GP-1-468-3 if it is approved by regulatory authorities and successfully commercialized.
 "We are very pleased with Marion Merrell Dow's decision to license GP-1-468-3 for clinical development," said David F. Hale, chairman, president and chief executive officer of Gensia. "We believe this is a strong indication of Marion Merrell Dow's interest in the potential of ARA technology for the treatment of chronic cardiovascular conditions."
 The agreement with Marion Merrell Dow is targeted at the research and development of orally active ARA compounds for the treatment of cardiovascular and cerebrovascular diseases. GP-1-468-3 is an analog of Arasine(TM), Gensia's leading therapeutic drug which has recently completed Phase 3 clinical trials in the United States, Western Europe and Canada in patients undergoing coronary artery bypass surgery.
 Marion Merrell Dow will continue investigating GP-1-468-3 to determine the safety, tolerance and oral bioavailability of the drug in human clinical trials. Marion Merrell Dow will have responsibility for and assume the cost of clinical development, regulatory filings, and following receipt of regulatory approval, manufacturing and marketing of GP-1-468-3 or any other orally active ARA licensed from Gensia in the United States, Canada, Europe, Australia, New Zealand and certain other international markets.
 "GP-1-468-3 has been tested by both Marion Merrell Dow and Gensia and appears to exhibit cardioprotective qualities in preclinical models of cardiovascular disease," said Hale. "Gensia will continue to consult with Marion Merrell Dow on the further development of GP-1-468-3. We are also continuing our research program under the agreement to discover new ARAs, with the potential for application in the treatment of chronic cardiovascular and cerebrovascular disease."
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel drugs for the treatment and diagnosis of human diseases.
 -0- 7/27/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA MKC) CO: Gensia Pharmaceuticals Inc.; Marion Merrill Dow Inc. ST: California IN: MTC SU:


LS-EH -- SD004 -- 3355 07/27/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:452
Previous Article:HONDA TO REDUCE U.S. ACCORD OUTPUT, AUTOMOTIVE NEWS REPORTS
Next Article:WEITEK ANNOUNCES WORLD'S FASTEST USER INTERFACE CONTROLLER FOR WINDOWS DESKTOP PUBLISHING AND CAD APPLICATIONS
Topics:


Related Articles
ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION ON DRUGS FOR DIABETES AND AGING
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
GENSIA ADOPTS STOCKHOLDER RIGHTS PLAN; APPOINTS CARL BOBKOSKI TO BOARD
MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION
CORTECH AND MARION MERRELL DOW ADD CLINICAL INDICATIONS AND AMEND LICENSE AGREEMENT IN NEUTROPHIL ELASTASE INHIBITOR PROGRAM
GENSIA RETAINS EXCLUSIVE MARKETING RIGHTS TO ARASINE
GENSIA AND ARAMED RECEIVE RIGHTS TO DEVELOP ORAL ARA COMPOUND FOR CARDIOVASCULAR DISEASE
ONCOGENE SCIENCE, INC. AND MARION MERRELL DOW COLLABORATIVE PROGRAM ADVANCES
AFFYMAX TO RECEIVE PROGRESS PAYMENTS FOR TWO COLLABORATIVE AGREEMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters